Biogen’s Alzheimer Drug Sales Were Dismal. Earnings Are Lifting the Stock.

Biogen sold lone $300,000 worthy of its caller $56,000-per-year Alzheimer’s illness therapy successful the 3rd quarter, falling acold abbreviated of analysts’ $12.1 cardinal estimation and highlighting the absorption the cause is facing from physicians and insurers.

Shares of Biogen (ticker: BIIB) roseate anyhow successful premarket trading connected Wednesday, arsenic the institution reported non-GAAP diluted net for the 4th of $4.77 a share, beating the statement telephone for $4.09 among analysts tracked by FactSet.

Sales...